[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Global Peptide Therapeutics Market & Clinical Pipeline Insight 2026

January 2020 | 1500 pages | ID: G979050138BEN
PNS Pharma

US$ 3,000.00

E-mail Delivery (PDF), Hard Copy Mail Delivery, CD-ROM Mail Delivery

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

“Global Peptide Therapeutics Market & Clinical Pipeline Insight 2026” report highlights:
  • Global Peptide Therapeutics Market Opportunity: US$ 65 Billion
  • Cancer Peptide Therapeutics Market Opportunity: US$ 22 Billion
  • Insight Peptide Drugs in Clinical Trials: 807 Peptides Drugs
  • Clinical & Patent Insight on 197 Marketed Peptides
  • Peptide Clinical Pipeline Is Dominated by Cyclic Peptides: 46 Peptides
  • Peptides Clinical Trials Insight by Phase, Indication & Company
  • Future Peptide Therapeutics Market Outlook
“Global Peptide Therapeutics Market & Clinical Pipeline Insight 2026” report gives comprehensive insight on clinical and non-clinical parameters involved in the development of global peptide drug market. As per report findings, peptides have emerged as one of the important classes of therapeutic molecules which have been developed by varied pharmaceutical and biotech companies in order to attain a targeted drug discovery for several ailments. Currently, there are more than 800 peptide drugs in clinical pipeline and 197 peptide based drugs commercially available in the market.

'Oncology Segment Will Continue To Dominate The Global Peptide Therapeutics Market In Terms Of Revenue Opportunity & Clinical Pipeline'

From the last several decades, therapeutic peptides and proteins have risen as potential drug candidate. Many companies are specializing in their manufacturing, along with companies developing peptide based products ranging from new drug candidates to medical diagnostic devices. The massive increase in the cost and time span to develop a conventional drugs led researchers and pharmaceutical companies to develop new cost effective products based of synthetic peptide strategy, which led to development large number of peptides of medical importance.

The lower toxicity levels of peptides can be credited to both their lower instance of interaction with other molecules not of interest and also to their ease of metabolism into their component amino acid residues. Pharmaceutical companies are attracted towards the peptides due to ease of manufacturing. In contrast to the old trial and error routines, nowadays the process starts with a clear understanding of the disease on a molecular level and based over the hypotheses of drug outcome, new drugs are designed.

The necessity of peptides as new innovative drug development has also been raised by the property of peptides being bioactive as considered one of the major interests of pharmaceuticals. As compared to synthetic substances peptides degrade into their component proteinogenic amino acid without leading to toxic metabolites. Furthermore, a disadvantage can sometimes be an advantage as peptides possess short half-lives which make them costly on one hand but advantage is less accumulation in the body.

'Global Peptide Drug Market Is Projected To Surpass US$ 60 Billion By 2026 Driven By Strong Clinical Pipeline & Favorable Commercialization Parameters '

In reference to these favorable attributes peptide drug market is flourishing and several peptide based therapeutics have been commercialized. With enhanced technologies, the prospects of the peptide drugs are getting influential day by day and new peptides are being discovered to be developed as peptide drug. Peptide therapeutics is completely different from the traditional way and may open a new window for finding completely new peptide drugs. Also, bioinformatics and systematic biological approaches help in searching for potential peptide drug candidates based on the knowledge and data.

The future potential of expanding peptide therapeutic market is contributed towards the characteristics like safety, targeted drug delivery and high specificity. Especially for illnesses requiring prolonged therapy, peptides have a competitive advantage over conventional small molecule drugs. Due to their extremely high specificity for their intended target, in combination with the fact that they are extra cellularly active, much lower amounts can be formulated.
1. INTRODUCTION TO PEPTIDE THERAPEUTICS

1.1 Overview & Historical Development
1.2 Why We Need Peptide Therapeutics?

2. FOUNDATION OF PEPTIDE THERAPEUTICS

2.1 Screening of Novel Peptide Molecules
2.2 Production of Therapeutic Peptides
2.3 Regulation over Peptide Therapeutics

3. KEY ASPECTS IN PEPTIDE DRUG DEVELOPMENT

3.1 Approaches to Overcome Peptide Associated Limitations
  3.1.1 Terminal Protection
  3.1.2 Non-Chemical Modifications
  3.1.3 Synthetic Amino Acid Substitution & Backbone Modification
  3.1.4 Computational Modifications for Improving Aqueous Solubility & Membrane Permeability
3.2 High-Throughput Screening (HTS) for New Peptide Entity

4. PEPTIDE THERAPEUTICS OVER TRADITIONAL MOLECULES

4.1 Peptides v/s Biological Proteins
4.2 Peptides v/s Small Molecules

5. GLOBAL PEPTIDE THERAPEUTICS MARKET SCENARIO

5.1 Market Overview
5.2 Market by Region
  5.2.1 North America
  5.2.2 Europe
  5.2.3 Asia
5.3 Peptide Therapeutic Market Segmentation by Application
  5.3.1 Peptides in Imaging
  5.3.2 Peptides in Diseases
5.4 Market by Route of Administration
  5.4.1 Current Scenerio
  5.4.2 Current Trends over Approved Peptide Products

6. GLOBAL PEPTIDE ONCOLOGY THEREUPETICS MARKET SCENARIO

6.1 Market Overview
6.2 Peptide Oncology Drug Market - Regional Segmentation

7. CANCER PEPTIDES DRUG COST, DOSAGE & PATENT INSIGHT

7.1 Firmagon (Degarelix)
7.2 Mepact (Mifamurtide)
7.3 Zoladex (Goserelin)
7.4 Eligard (Leuprolide)
7.5 Lupron (Leuprolide Acetate)
7.6 Plenaxis (Abarelix)
7.7 Trelstar (Treptorelin)
7.8 Decapeptyl SR (Treptorelin Acetate or Pamoate)
7.9 Octreotide
7.10 Sandostatin (Octeriotide Acetate)
7.11 Velcade (bortizomib)
7.12 Cosmegen (Dactinomycin)
7.13 Somatuline Depot (lanreotide)
7.14 Suprefact (Buserelin)
7.15 Ninlaro (Ixazomib)
7.16 Kyprolis (Carfilzomib)
7.17 Gonax (Degarelix Acetate)

8. PEPTIDE THERAPEUTICS IN CARDIOVASCULAR DISEASE

8.1 Overview to Global Cardiovascular Diseases Burden
8.2 Peptide Drugs in Cardiovascular Diseases – Availability & Cost Analysis
8.3 Cardiac Peptide Therapeutics – Sales Analysis

9. PEPTIDE THERAPEUTICS IN METABOLIC DISORDER

9.1 Overview to Global Metabolic Disorders Burden
9.2 Peptide Drugs for Metabolic Disorders – Availability, Cost & Dosage Analysis
9.3 Market of Metabolic Peptides

10. PEPTIDE THERAPEUTICS FOR INFECTIONS

10.1 Overview to Infectious Diseases
10.2 Global - HIV Infection Burden
10.3 Commercially Available Anti-Infective Peptide Drugs
10.4 Anti-Infectious Peptide Drugs - Regional & Sales Analysis

11. PEPTIDE THERAPEUTICS AGANIST CNS DISORDERS

11.1 Overview to CNS Disorders
11.2 Approaches for Developing Neuropeptide Drugs
11.3 Opportunities for Neuropeptide Drug Market

12. GLOBAL PEPTIDES DRUG CLINICAL INSIGHT BY TYPE

12.1 Dipeptides
12.2 Cyclic Peptides
12.3 Depsipeptides
12.4 Glucagon-Like Peptide
12.5 Glycopeptides
12.6 Insulin
12.7 Lipopeptides
12.8 Natriuretic Peptides
12.9 Neuropeptides
12.10 Oligopeptides
12.11 Opioid Peptides
12.12 Peptide Homone
12.13 Peptides
12.14 Peptide Fragments
12.15 Peptide Vaccine
12.16 Multiple Peptides

13. GLOBAL PEPTIDE DRUG MARKET DYNAMICS – CHALLENGES & DRIVERS

13.1 Global Peptide Drug Market Drivers
13.2 Challenges for Global Peptide Drug Market

14. GLOBAL PEPTIDE THERAPEUTICS MARKET FUTURE PANORAMA

14.1 Future Trends in Peptide Therapeutics
14.2 Peptides Therapeutics Market Opportunities

15. OLIGOPEPTIDES CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

15.1 Preclinical
15.2 Phase-I
15.3 Phase-I/II
15.4 Phase-II
15.5 Phase-III
15.6 Preregistration
15.7 Registered
15.8 Marketed

16. INSULIN CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

16.1 Unknown
16.2 Research
16.3 Preclinical
16.4 Clinical
16.5 Phase-I
16.6 Phase-I/II
16.7 Phase-II
16.8 Phase-II/III
16.9 Phase-III
16.10 Preregistration
16.11 Registered
16.12 Marketed

17. PEPTIDE HORMONE CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

17.1 Unknown
17.2 Research
17.3 Preclinical
17.4 Clinical
17.5 Phase-I
17.6 Phase-I/II
17.7 Phase-II
17.8 Phase-III
17.9 Preregistration
17.10 Marketed

18. PEPTIDE CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

18.1 Unknown
18.2 Research
18.3 Preclinical
18.4 Clinical
18.5 Phase-I
18.6 Phase-I/II
18.7 Phase-II
18.8 Phase-II/III
18.9 Phase-III
18.10 Preregistration
18.11 Registered
18.12 Marketed

19. GLUCAGON-LIKE PEPTIDE CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

19.1 Preclinical
19.2 Clinical
19.3 Phase-I
19.4 Phase-II
19.5 Phase-III
19.6 Preregistration
19.7 Marketed

20. GLYCOPEPTIDE CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

20.1 Preclinical
20.2 Phase-I
20.3 Phase-I/II
20.4 Marketed

21. MULTIPLE PEPTIDE CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

21.1 Research
21.2 Preclinical
21.3 Phase-I
21.4 Phase-II
21.5 Phase-II/III
21.6 Phase-III
21.7 Preregistration
21.8 Registered
21.9 Marketed

22. PEPTIDE VACCINE CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

22.1 Preclinical
22.2 Phase-I
22.3 Phase-I/II
22.4 Phase-II
22.5 Phase-III
22.6 Registered
22.7 Marketed

23. CYCLIC PEPTIDE CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

23.1 Unknown
23.2 Research
23.3 Preclinical
23.4 Phase-I
23.5 Phase-II
23.6 Phase-II/III
23.7 Phase-III
23.8 Preregistration
23.9 Registered
23.10 Marketed

24. PEPTIDE FRAGMENT CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

24.1 Research
24.2 Preclinical
24.3 Phase-I
24.4 Phase-I/II
24.5 Phase-II
24.6 Phase-II/III
24.7 Preregistration
24.8 Registered
24.9 Marketed

25. DIPEPTIDE CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

25.1 Preclinical
25.2 Phase-I
25.3 Phase-I/II
25.4 Phase-II
25.5 Phase-III
25.6 Registered
25.7 Marketed

26. OPIOID PEPTIDE CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

26.1 Phase-I/II
26.2 Phase-II
26.3 Preregistration
26.4 Registered
26.5 Marketed

27. DEPSIPEPTIDE CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

27.1 Preclinical
27.2 Phase-I
27.3 Registered
27.4 Marketed

28. NATRIURETIC PEPTIDE CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

28.1 Research
28.2 Phase-II
28.3 Phase-III
28.4 Marketed

29. NEUROPEPTIDE CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

29.1 Research
29.2 Preclinical
29.3 Phase-I
29.4 Phase-I/II
29.5 Phase-II
29.6 Marketed

30. PITUITARY GONADOTROPIN CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

30.1 Unknown
30.2 Preclinical
30.3 Phase-I
30.4 Phase-II
30.5 Phase-III
30.6 Marketed

31. LIPOPEPTIDE CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

31.1 Research
31.2 Preclinical
31.3 Phase-II
31.4 Phase-III

32. PEPTIDE APTAMER CLINICAL PIPELINE BY COMPANY, INDICATION & PHASE

32.1 Preclinical
32.2 Phase-I
32.3 Phase-I/II
32.4 Phase-III

33. COMPETITIVE LANDSCAPE

33.1 Amgen
33.2 Amylin Pharmaceuticals
33.3 Apitope Technology
33.4 BioPartners
33.5 BiondVax Pharmaceuticals Ltd
33.6 Boehringer Ingelheim
33.7 Circassia
33.8 Corden Pharma (Peptisyntha)
33.9 Eli Lily
33.10 Galena Biopharmaceuticals
33.11 GlaxoSmithKline
33.12 Hyperion Therapeutics
33.13 ImmunoCellular Therapeutics
33.14 Ipsen
33.15 Lonza
33.16 Merck
33.17 NovoNordisk
33.18 Par Pharmaceuticals
33.19 PeptiDream
33.20 Roche
33.21 Sanofi
33.22 Tarix Pharmaceuticals

LIST OF FIGURES

Figure 2-1: Classification of Peptides by Sources
Figure 2-2: Screening Approaches of Novel Therapeutics peptides
Figure 2-3: Methods for Large Scale Production of Therapeutic Peptides
Figure 2-4: General Concept of Manufacturing of Peptide Drugs
Figure 2-5: Process of Peptide Therapeutics FDA Approval Path
Figure 3-1: Different Approaches Used for Overcoming Peptide Drugs Associated Limitations
Figure 4- 1: Peptides as a Cusp of Small Molecule Drug & Proteins
Figure 4- 2: Advantages of Peptide Drugs
Figure 5-1: Global - Imaging Technology Market by Usage (%), 2018
Figure 5-2: Healthcare Imaging Market Share by Company (%), 2018
Figure 5-3: Diagrammatic Representation of the Peptidic Probe
Figure 5-4: Distribution of Therapeutic Drugs Approved by FDA by Chemical Species
Figure 5-5: Global - Peptide Therapeutics Market Size by Clinical Indications, 2018
Figure 5-6: Global - Insulin Market Forecast (US$ Billion) 2018 - 2026
Figure 5-7: Therapeutic Peptide Based Drugs over Route of Administration
Figure 6-1: Global - Peptide Therapeutics Market Forecast (US$ Billion), 2018 - 2026
Figure 6-2: Global – Total Peptide Therapeutic Market Size vs. Oncological Peptide
Therapeutic Market Size (US$ Billion), 2019
Figure 6-3: Global – Peptide Oncology Drugs Market Size (US$ Billion), 2018 - 2026
Figure 6-4: Peptide Oncology Market – Regional Market Share (%), 2018
Figure 7-1: Classification of Therapeutic Peptides
Figure 7-2: Frimagon – Years of Different Patent Issue
Figure 7-3: Frimagon – Expiration Year of Different Patents
Figure 7-4: Frimagon - Cost of 80mg & 120mg Supply of Powder for Subcutaneous Injection (US$), October’2019
Figure 7-5: Firmagon - Starting & Maintenance Dosage (mg)
Figure 7-6: Firmagon – Treatment Cost of Initial Month, Maintenance Month & Annually (US$), October’2019
Figure 7-7: Mepact - Recommended Number of Dose Administration/ Week for 12 & 24 Weeks Treatment
Figure 7-8: Germany - Mepact Full Treatment Cost for Children & Adults (US$ Millions), October’2019
Figure 7-9: Zoladex – Patent Issue & Expiration Year
Figure 7-10: Zoladex - Cost of 3.6mg & 10.8mg Implant (US$), October’2019
Figure 7-11: Zoladex – Recommended Dose for Prostate cancer Management on Monthly Basis (MG), October’2019
Figure 7-12: Zoladex – Annual Treatment Cost using 3.6mg & 10.8mg Implant (US$), October’2019
Figure 7-13: Eligard – Patent Issue & Expiration Year
Figure 7-14: Eligard - Cost of Different doses of Extended Release Subcutaneous Powder for Injection (US$), October’2019
Figure 7-15: Eligard – Recommended Dosage for Porstate Cancer on Monthly Basis (mg)
Figure 7-16: Eligard – Annual Treatment cost of Prostate Cancer using Different available Doses (US$), October’2019
Figure 7-17: Eligard – Recomended Dose for Treatment of Uterine Leiomyomata on Monthly Basis (mg), October’2019
Figure 7-18: Eligard – Cost Per Month & Full Treatment Cost of Uterine Leiomyomata using 7.5mg Dose (US$), October’2019
Figure 7-19: Lupron – Patent Issue & Expiration Year for Controlled Release Preparation
Figure 7-20: Lupron – Patent Issue & Expiration Year for Sustained Release Preparation
Figure 7-21: Lupron – Price for 7.5mg, 22.5mg, 30mg & 40mg Depot (US$), October’2019
Figure 7-22: Lupron – Recommended Dosage for Prostate Cancer Treatment on Monthly Basis (mg)
Figure 7-23: Lupron – Annual Treatment Cost of Prostate Cancer Treatment using Different Available Doses (US$), October’2019
Figure 7-24: Lupron – Recomended Dose for Treatment of Uterine Leiomyomata on Monthly Basis (mg), October’2019
Figure 7-25: Lupron – Cost per Month & Full Treatment Cost of Uterine Leiomyomata using 7.5mg Depot (US$), October’2019
Figure 7-26: Plenaxis – Number of Recommended Doses on Monthly Basis
Figure 7-27: Plenaxis – Initial, Maintenance & Full Treatment Cost (US$), October’2019
Figure 7-28: Trelstar – Patent Issue & Expiration Year
Figure 7-29: Trelstar - Cost for a Supply of 3.75mg, 11.25mg & 22.5mg Powder for Intramuscular Injection (US$), October’ 2019
Figure 7-30: Trelstar - Recommended Dose for Prostate Cancer Treatment (mg), October’2019
Figure 7-31: Trelstar – Annual Treatment Cost using 3.75 mg, 11.25mg & 22.5mg Powder for Intramuscular Injection (US$), October’2019
Figure 7-32: Decapeptyl SR – Price for a Supply of 3mg, 11.25mg & 22.5mg Powder for Injection (US$), October’2019
Figure 7-33: Decapeptyl SR - Recommended Dosage for Prostate Cancer Treatment on Monthly Basis (mg)
Figure 7-34: Decapeptyl SR - Annual Treatment Cost of Prostate Cancer Treatment using Different Available Doses (US$), October’2019
Figure 7-35: Octreotide - Cost of Different Commercially Available mg/ml Doses of Octreotide for 10 ml Supply (US$), October’2019
Figure 7-36: Octreotide – Average Initial Dose for Treatment of Carcinoid Tumor & Vasoactive Intestinal Peptide Tumor (mg), October’2019
Figure 7-37: Sandostatin – Price for 10 Vial Supply & per Unit Price of 50mcg/ml Injectable Solution (US$), October’2019
Figure 7-38: Sandostatin – Price for 10 Vial Supply & per Unit Price of 100mcg/ml Injectable Solution (US$), October’2019
Figure 7-39: Sandostatin – Price for 10 Vial Supply & per Unit Price of 500mcg/ml Injectable Solution (US$), October’2019
Figure 7-40: Sandostatin - Mean Initial Dose for Treatment of Carcinoid Tumor & Vasoactive Intestinal Peptide Tumor (mg), October’2019
Figure 7-41: Velcade – 1st & 2nd Patent Issue & Expiration Year
Figure 7-42: Velcade – Price of 3.5mg Supply & Full Treatment Cost for Multiple myeloma (US$), October’2019
Figure 7-43: Cosmegen – Average Cost of once in 3 Week & once in 6 Week Treatment Cycle for Wilm’s Tumor using 0.5mg Powder for Injection (US$), October’2019
Figure 7-44: Cosmegen – Treatment Cost of One Cycle & Full Treatment Cost of Rhabdomyosarcoma (US$), October’2019
Figure 7-45: Cosmegen – Treatment Cost of One Cycle & Full Treatment Cost of Ewing’s Tumor (US$), October’2019
Figure 7-46: Cosmegen – Treatment Cost of One Cycle & Full Treatment Cost of Testicular Cancer (US$), October’2019
Figure 7-47: Cosmegen – Full Treatment Cost as Monotherapy & Combinational Therapy in Trophoblastic Disease (US$), October’2019
Figure 7-48: Cosmegen – Full Treatment Cost of Upper & lower Body Solid Tumor (US$), October’2019
Figure 7-49: Somatuline Depot – Patent Issue & Expiration Year
Figure 7-50: Somatuline Depot – Price of 60mg/0.2 ml Supply & Price per unit of Somatulin Depot Subcutaneous Solution (US$), October’2019
Figure 7-51: Somatuline Depot – Price of 90mg/0.3ml Supply & Price per unit of Somatulin Depot Subcutaneous Solution (US$), October’2019
Figure 7-52: Somatuline Depot – Price of 120mg/0.5ml Supply & Price per unit of Somatulin Depot Subcutaneous Solution (US$), October’2019
Figure 7-53: Somatuline Depot – Treatment cost of 1 Cycle & Annual Treatment Cost of GEP-NETs & Carcinoid Syndrome (US$), October’2019
Figure 7-54: Suprefact – Price of 6.3mg & 9.45mg Depot (US$), October’2019
Figure 7-55: Suprefact – Cost for a Supply of 1ml/ml Nasal Spray and Injectable solution (US$), October’2019
Figure 7-56: Suprefact Injection – Recommended Initial Dose & Final Dose For Prostate Cancer Treatment (mg/Day), October’2019
Figure 7-57: Suprefact Depot – Recommended Dose for Prostate Cancer Treatment on Monthly Basis (mg), October’2019
Figure 7-58: Suprefact Depot – Annual Prostate Cancer Treatment Cost (US$), October’2019
Figure 7-59: Ninlaro – Patent Issue & Expiration Year
Figure 7-60: Ninlaro – Price for 3 Capsule Supply & Price per Unit of Ninlaro Capsule (US$), October’2019
Figure 7-61: Ninlaro – Recommended Dose & Dose Reductions for Treatment of Multiple Myeloma (Mg/Week), October’2019
Figure 7-62: Ninlaro – Cost of 1 Treatment Cycle & Full Treatment Cost for Multiple Myeloma (US$), October’2019
Figure 7-63: Kyprolis – Issue & Expiration Year of Patents Assigned to Proteolix Inc.
Figure 7-64: Kyprolis – Issue & Expiration Year of Patent Assigned to Cydex Pharmaceuticals
Figure 7-65: Kyprolis – Issue & Expiration Year of Patents Assigned to Onyx Therapeutics
Figure 7-66: Kyprolis – Price of 10mg, 30mgg & 60mg Intraveneous Powder for Injection (US$), October’2019
Figure 7-67: Kyprolis – Initial Dose & Maintainence Dose for Treatment of Multiple Myeloma (mg/m2 Per Week)
Figure 7-68: Kyprolis - Initial Dose & Maintainence Dose as Monotherapy for Treatment of Multiple Myeloma (mg/m2 Per Week)
Figure 7-69: Gonax - Cost of 80mg & 120mg Supply of Powder for Subcutaneous Injection (US$), October’2019
Figure 7-70: Gonax - Starting & Maintenance Dosage (mg)
Figure 7-71: Gonax – Treatment Cost of Initial Month, Maintenance Month & Annually (US$), October’2019
Figure 8-1: Global - Cardiovascular Mortality (%), 2018
Figure 8-2: Cardiovascular Peptide Therapeutics - Cost Analysis (US$//Patient), 2018
Figure 8-3: Global - Angiomax Sales (US$ Million), 2018
Figure 8-4: Global - Integrilin Sales (US$ Million), 2016 & 2017
Figure 9-1: Global - Prevalence of Metabolic Disorders by Region (%), 2018
Figure 9-2: Layout of Metabolic Syndrome Leading to Several Diseases
Figure 9-3: Global - Top 10 Countries with Diabetes Burden (Million), 2030
Figure 9-4: Global – Obesity in Women & Men by Region (Million), 2018
Figure 9-5: US– GLP-1 Agonist Drugs Comparative Cost Analysis (US$), 2018
Figure 9-6: Lantus – Monthly Cost Comparison by Country (US$), 2018
Figure 9-7: Global – Metabolic Peptide Market Size (%), 2018
Figure 10-1: Global - Top 10 Leading Causes of Death
Figure 10-2: Global – Distribution of AIDS Affected Patients by Region (%), 2018
Figure 10-3: Fuzeon - Global Sales (US$ Millions), 2015 - 2017
Figure 11-1: US - Prevalence of Alzheimer’s disease (Million)
Figure 11-2: Alzheimer Disease Market Size (%), 2018
Figure 12-1: Global - Total Peptides Clinical Pipeline by Phase (%), 2018 till 2024
Figure 12-2: Global Total Peptides Clinical Pipeline by Phase (Number), 2018 till 2024
Figure 12-3: Global - Dipeptides Clinical Pipeline by Phase (%),2019 till 2026
Figure 12-4: Global - Dipeptides Clinical Pipeline by Phase (Number), 2019 till 2026
Figure 12-5: Global - Cyclic Peptides Clinical Pipeline by Phase (%),2019 till 2026
Figure 12-6: Global - Cyclic Peptides Clinical Pipeline by Phase (Number), 2019 till 2026
Figure 12-7: Global - Depsipeptides Clinical Pipeline by Phase (%),2019 till 2026
Figure 12-8: Global - Depsipeptides Clinical Pipeline by Phase (Number), 2019 till 2026
Figure 12-9: Global - Glucagon-Like Peptide Clinical Pipeline by Phase (Number), 2019 till 2026
Figure 12-10: Global - Glucagon-Like Peptide Clinical Pipeline by Phase (%),2019 till 2026
Figure 12-11: Global - Glycopeptides Clinical Pipeline by Phase (%),2019 till 2026
Figure 12-12: Global - Glycopeptides Clinical Pipeline by Phase (Number), 2019 till 2026
Figure 12-13: Global - Insulin Clinical Pipeline by Phase (Number), 2019 till 2026
Figure 12-14: Global - Insulin Clinical Pipeline by Phase (%), 2019 till 2026
Figure 12-15: Global - Lipopeptides Clinical Pipeline by Phase (%),2019 till 2026
Figure 12-16: Global - Lipopeptides Clinical Pipeline by Phase (Number), 2019 till 2026
Figure 12-17: Global - Natriuretic Peptides Clinical Pipeline by Phase (%),2019 till 2026
Figure 12-18: Global - Natriuretic Peptides Clinical Pipeline by Phase (Number), 2019 till 2026
Figure 12-19: Global - Neuropeptides Clinical Pipeline by Phase (%),2019 till 2026
Figure 12-20: Global - Neuropeptides Clinical Pipeline by Phase (Number), 2019 till 2026
Figure 12-21: Global - Oligopeptides Clinical Pipeline by Phase (%),2019 till 2026
Figure 12-22: Global - Oligopeptides Clinical Pipeline by Phase (Number), 2019 till 2026
Figure 12-23: Global - Opioid Peptides Clinical Pipeline by Phase (%),2019 till 2026
Figure 12-24: Global - Opioid Peptides Clinical Pipeline by Phase (Number), 2019 till 2026
Figure 12-25: Global - Peptide Hormone Clinical Pipeline by Phase (Number), 2019 till 2026
Figure 12-26: Global - Peptide Hormone Clinical Pipeline by Phase (%),2019 till 2026
Figure 12-27: Global - Peptides Clinical Pipeline by Phase (%),2019 till 2026
Figure 12-28: Global - Peptides Clinical Pipeline by Phase (Number), 2019 till 2026
Figure 12-29: Global - Peptide Fragments Clinical Pipeline by Phase (%),2019 till 2026
Figure 12-30: Global - Peptide Fragments Clinical Pipeline by Phase (Number), 2019 till 2026
Figure 12-31: Global - Peptide Vaccine Clinical Pipeline by Phase (%),2019 till 2026
Figure 12-32: Global - Peptide Vaccine Clinical Pipeline by Phase (Number), 2019 till 2026
Figure 12-33: Global - Multiple Peptides Clinical Pipeline by Phase (%),2019 till 2026
Figure 12-34: Global - Multiple Peptides Clinical Pipeline by Phase (Number), 2019 till 2026
Figure 13-1: Illustration of Peptide Therapeutics Market Drivers
Figure 13-2: Major Challenges Faced by the Peptide Therapeutics
Figure 14-1: Global – Estimated Future Peptide Therapeutics Market Size by Clinical Indication (%), 2026
Figure 14-2: Global - Cancer Peptide Therapeutics Forecast (US$ Billion), 2018 - 2024
Figure 14-3: Future Trends of Peptide Therapeutics

LIST OF TABLES

Table 4-1: Comparative Differentiation between Peptide & Protein Drugs
Table 4-2: Comparative Analysis of Small Molecules & Peptide Drugs
Table 5-1: List of Approved Peptide Drugs Since 2000
Table 7-1: Peptide Based Drugs
Table 8-1: Approved Peptide Drugs for Cardiovascular Diseases
Table 9-1: Major Approved GLP-1 Peptide Drugs for Metabolic Disorders
Table 9-2: Layout of Insulin & its Analogs Cost in US
Table 10-1: Approved Drugs for Infections
Table 11-1: Brief Characterization of Some Neuroprotective Peptides
Table 11-2: Potential Targets for Peptide Based Therapies in CNS Disorders


More Publications